after reading prelim final report (31/8) & ann. on 18/9 re...

after reading prelim final report (31/8) & ann. on 18/9 re proposed asset sales (if Kedron transaction proceeds) now find valuations more problematical

LFE had intended to pay off US$10 to 20M of debt so that has to be factored into valuations if latest offer is accepted

offsetting that LFE values anti-D red cell line (whatever that is) at US$20M, I assume they would still control that asset?

cheers